ReGen Biologics Participates in 2007 AANA Annual Meeting.

FRANKLIN LAKES, N.J. -- ReGen Biologics (OTC: RGBI) will exhibit the company's products at the Arthroscopy Association of North America (AANA) meeting, being held this week in San Francisco.

Additionally, data from its CMI[TM] product clinical trial will be highlighted in two podium presentations and two "e-posters" as part of the scientific program offered to attending surgeons.

The first presentation focuses on the correlation between tissue loss and clinical symptoms, function and activity levels following meniscectomy. The second underscores the decreased rate of re-operations for chronic patients receiving a collagen meniscus implant. Both presentations are scheduled for this afternoon.

The e-posters are available for review throughout the meeting. One features the latest suture techniques being used for fixation of the collagen meniscus implant and the other documents new tissue growth and increased activity level in patients two years following a collagen meniscus implant procedure.

"The AANA meeting provides an excellent forum for ReGen management and clinical collaborators to meet and discuss our latest clinical data," said Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics.

Copies of presentation and poster abstracts will be available on the ReGen corporate website following the completion of the AANA annual meeting at www.regenbio.com.

The stated goal of the AANA is to promote, encourage, support and foster through continuing medical education functions, the development and dissemination of knowledge in the discipline of arthroscopic surgery. For more information on the annual meeting, or scheduled presentations visit www.aana.org.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen's first approved product using its collagen scaffold technology is the CMI[TM], a meniscus application, which is cleared for sale in Europe and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA. For more information on ReGen, visit www.regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the Web site maintained by the SEC at http://www.sec.gov.